

## First Outbreak of *Klebsiella pneumoniae* Clinical Isolates Producing GES-5 and SHV-12 Extended-Spectrum $\beta$ -Lactamases in Korea

Seok Hoon Jeong, Il Kwon Bae, Doelman Kim, Seong Geun  
Hong, Jae Seok Song, Jung Hun Lee and Sang Hee Lee  
*Antimicrob. Agents Chemother.* 2005, 49(11):4809. DOI:  
10.1128/AAC.49.11.4809-4810.2005.

---

Updated information and services can be found at:  
<http://aac.asm.org/content/49/11/4809>

---

*These include:*

### REFERENCES

This article cites 12 articles, 8 of which can be accessed free at:  
<http://aac.asm.org/content/49/11/4809#ref-list-1>

### CONTENT ALERTS

Receive: RSS Feeds, eTOCs, free email alerts (when new  
articles cite this article), [more»](#)

---

---

Information about commercial reprint orders: <http://journals.asm.org/site/misc/reprints.xhtml>  
To subscribe to to another ASM Journal go to: <http://journals.asm.org/site/subscriptions/>

---

## First Outbreak of *Klebsiella pneumoniae* Clinical Isolates Producing GES-5 and SHV-12 Extended-Spectrum $\beta$ -Lactamases in Korea

*Klebsiella pneumoniae* clinical isolates producing extended-spectrum  $\beta$ -lactamases (ESBLs; TEM and SHV types) are frequently implicated in hospital outbreaks. There are also reports of *K. pneumoniae* isolates producing various non-TEM, non-SHV ESBLs: CTX-M and GES/IBC types (1). Presently, the different GES-type ESBLs are designated by identical names (8). To clarify the misleading nomenclature of GES-type ESBLs, we propose maintaining the current denomination concerning the fully characterized GES-3 and GES-4 ESBLs reported by Wachino et al. (12, 13) and renaming the variants (GES-3 and GES-4) reported by Vourli et al. (11) as GES-5 and GES-6, respectively.

In 2004, six *K. pneumoniae* clinical isolates producing ESBLs were collected from different patients and distributed among several wards (intensive care unit, neurosurgery, pulmonary internal medicine, and general medicine) at Bundang CHA Medical Center, Republic of Korea. These isolates were identified from sputum samples (for three isolates), urine (for one isolate), bile (for one isolate), and pus (for one isolate).

Antibiotic susceptibility testing by disk diffusion tests that were performed according to the recommendations of the Clinical and Laboratory Standards Institute (2) with BBL (Cockeysville, Md.) disks and by the double-disk synergy test of Jarlier et al. (4) suggested the presence of ESBL(s). Double-disk synergies were observed for amoxicillin-clavulanic acid (CLA), ceftazidime, cefotaxime, and aztreonam. All isolates were resistant to penicillins, ceftazidime, cefotaxime, aztreonam, tobramycin, gentamicin, and trimethoprim-sulfamethoxazole. They were susceptible to cefepime and represented reduced susceptibility to imipenem.

The analysis of genomic DNA, digested with SpeI and resolved by pulsed-field gel electrophoresis (PFGE) (5), revealed the same macrorestriction pattern among all isolates, which were therefore classified as indistinguishable.

Screening for ESBL gene(s) was performed by PCR using the primers for *bla*<sub>TEM</sub>, *bla*<sub>SHV</sub>, *bla*<sub>GES</sub>, *bla*<sub>PER</sub>, *bla*<sub>VEB</sub>, *bla*<sub>TOHO</sub>, *bla*<sub>SFO</sub>, *bla*<sub>BES</sub>, *bla*<sub>FEC</sub>, *bla*<sub>CME</sub>, *bla*<sub>TLA</sub>, *bla*<sub>CTX-M</sub>, and *bla*<sub>OXA</sub> (1, 5, 7, 10). PCR amplification experiments using primers designed to amplify GES- and SHV-type ESBL genes gave only positive results for all isolates. The nucleotide sequence of the respective amplicon for the *bla*<sub>SHV</sub> gene revealed 100% identity with *bla*<sub>SHV-12</sub> from *K. pneumoniae* (6). That for the *bla*<sub>GES</sub> gene differs by only one silent mutation (G→A) at position 54 from *bla*<sub>GES-5</sub>, described elsewhere for *Escherichia coli* (11). On the isoelectric focusing gel, two  $\beta$ -lactamase activities with pIs of 5.8 and 8.2 were detected in all isolates. On the basis of DNA sequencing and pI values, the  $\beta$ -lactamase activity of pI 8.2 corresponds to that of SHV-12  $\beta$ -lactamase, and the pI value of 5.8 represents GES-5  $\beta$ -lactamase.

Six isolates were used as donors in transconjugation experiments. Ceftazidime-resistant transconjugants were obtained in all cases at frequencies ranging from  $10^{-4}$  to  $10^{-5}$  per donor cell. All transconjugants produced only GES-5. The SHV-12 gene was not cotransferred, indicating that the *bla* genes for GES-5 and SHV-12 resided on different genetic elements. All GES-5-producing transconjugants were resistant to penicillins and ceftazidime and susceptible to cefoxitin, cefotaxime, and

aztreonam. This phenotype is characteristic of GES/IBC-producing *Enterobacteriaceae* (9–13). All transconjugants were susceptible to cefepime and showed reduced susceptibilities to imipenem. MICs of ticarcillin, ceftazidime, and cefotaxime were reduced by clavulanic acid (Table 1). This resistance was due to the acquisition of large (>70-kb) plasmids that exhibited identical HindIII restriction patterns and harbored the GES-5 ESBL gene. Due to the presence of SHV-12 in all isolates, the MIC patterns of clinical isolates were different from those of their transconjugants.

The carbapenemase bioassay (the modified cloverleaf test) (5) showed that extracts derived from all transconjugants producing GES-5 supported growth of the indicator, *E. coli* ATCC 25922, in the presence of an imipenem disk (30  $\mu$ g), resembling the effect of OXA-23, which was used as a positive control. In contrast, cell extracts of a ceftazidime-sensitive *K. pneumoniae* clinical isolate collected from the Bundang CHA Medical Center did not cause any visible inhibition of carbapenemase activity. These findings indicated that the reduced susceptibilities of all isolates and their transconjugants to imipenem were due to production of GES-5 ESBL with the detectable carbapenemase activity.

Finding the same macrorestriction pattern by PFGE indicated that an endemic *K. pneumoniae* strain producing GES-5 and SHV-12 ESBLs was present in different wards at the Bundang CHA Medical Center in 2004. Six GES-5-producing transconjugants were also resistant to tobramycin, gentamicin, and trimethoprim-sulfamethoxazole. Although the complete nucleotide sequences of integrons from six clinical isolates were not determined, screening for the presence of class 1 through 4 integrase genes from large plasmids by PCR with primer pairs previously described (3) revealed the presence of class 1 integrons. The complete class 1 integron mapping of large plasmids from six clinical isolates and the possible spread of the GES-5 ESBL gene to other Korean hospitals are currently under investigation.

TABLE 1. MICs of  $\beta$ -lactams for ESBL-producing *K. pneumoniae* clinical isolates, their transconjugants, and the azide-resistant *E. coli* J53 recipient

$\beta$ -Lactam	MIC ( $\mu$ g/ml) for:		
	<i>K. pneumoniae</i> clinical isolates (GES-5, SHV-12)	Trc (GES-5) <sup>b</sup>	Azide-resistant <i>E. coli</i> J53
Ticarcillin	>256	128	2
Ticarcillin + CLA <sup>a</sup>	128–256	32	2
Cefoxitin	4–8	4	2
Ceftazidime	128–>256	32	0.125
Ceftazidime + CLA	16–64	1	0.125
Cefotaxime	64–128	1	0.06
Cefotaxime + CLA	8–32	0.25	0.06
Aztreonam	64–256	0.5	0.06
Imipenem	0.5–1	0.5	0.06

<sup>a</sup> CLA was used at a fixed concentration of 2  $\mu$ g/ml.

<sup>b</sup> Trc, transconjugant.

This work was funded by a Korea Research Foundation grant (KRF-2004-042-E00117).

## REFERENCES

1. Bradford, P. A. 2001. Extended-spectrum  $\beta$ -lactamases in the 21st century: characterization, epidemiology and detection of this important resistance threat. *Clin. Microbiol. Rev.* **14**:933–951.
2. Clinical and Laboratory Standards Institute. 2005. Performance standards for antimicrobial disk susceptibility tests, 8th ed. Approved standard M2-A8. Clinical and Laboratory Standards Institute, Wayne, Pa.
3. Goldstein, C., M. D. Lee, S. Sanchez, C. Hudson, B. Phillips, B. Register, M. Grady, C. Liebert, A. O. Summers, D. G. White, and J. J. Maurer. 2001. Incidence of class 1 and 2 integrase in clinical and commensal bacteria from livestock, companion animals, and exotics. *Antimicrob. Agents Chemother.* **44**:723–726.
4. Jarlier, V., M.-H. Nicolas, G. Fournier, and A. Philippon. 1988. Extended broad-spectrum  $\beta$ -lactamases conferring transferable resistance to newer  $\beta$ -lactam agents in *Enterobacteriaceae*: hospital prevalence and susceptibility patterns. *Rev. Infect. Dis.* **10**:867–878.
5. Jeon, B.-C., S. H. Jeong, I. K. Bae, S. B. Kwon, K. Lee, D. Young, J. H. Lee, J. S. Song, and S. H. Lee. 2005. Investigation of a nosocomial outbreak of imipenem-resistant *Acinetobacter baumannii* producing the OXA-23  $\beta$ -lactamase in Korea. *J. Clin. Microbiol.* **43**:2241–2245.
6. Jeong, S. H., I. K. Bae, J. H. Lee, S. H. Sohn, G. H. Kang, G. J. Jeon, Y. H. Kim, B. C. Jeong, and S. H. Lee. 2004. Molecular characterization of extended-spectrum  $\beta$ -lactamases produced by clinical isolates of *Klebsiella pneumoniae* and *Escherichia coli* from a Korean nationwide survey. *J. Clin. Microbiol.* **42**:2902–2906.
7. Lee, S. H., J. Y. Kim, S. H. Shin, S. K. Lee, M. M. Choi, I. Y. Lee, Y. B. Kim, J. Y. Cho, W. Jin, and K. J. Lee. 2001. Restriction fragment length dimorphism-PCR method for the detection of extended-spectrum  $\beta$ -lactamases unrelated to TEM- and SHV-types. *FEMS Microbiol. Lett.* **200**:157–161.
8. Lee, S. H., S. H. Jeong, J.-I. Wachino, Y. Arakawa, L. Poirel, and P. Nordmann. 2005. Nomenclature of GES-type extended-spectrum  $\beta$ -lactamases. *Antimicrob. Agents Chemother.* **49**:2148–2150.
9. Poirel, L., G. F. Weldhagen, T. Naas, C. D. Champs, M. G. Dove, and P. Nordmann. 2001. GES-2, a class A  $\beta$ -lactamase from *Pseudomonas aeruginosa* with increased hydrolysis of imipenem. *Antimicrob. Agents Chemother.* **45**:2598–2603.
10. Poirel, L., I. L. Thomas, T. Naas, A. Karim, and P. Nordmann. 2000. Biochemical sequence analyses of GES-1, a novel class A extended-spectrum  $\beta$ -lactamase, and the class 1 integron IN52 from *Klebsiella pneumoniae*. *Antimicrob. Agents Chemother.* **44**:622–632.
11. Vourli, S., P. Giakkoupi, V. Miriagou, E. Tzelepi, A. C. Vatopoulos, and L. S. Tzouvelekis. 2004. Novel GES/IBC extended-spectrum  $\beta$ -lactamase variants with carbapenemase activity in clinical enterobacteria. *FEMS Microbiol. Lett.* **234**:209–213.
12. Wachino, J.-I., Y. Doi, K. Yamane, N. Shibata, T. Yagi, T. Kubota, H. Ito, and Y. Arakawa. 2004. Nosocomial spread of ceftazidime-resistant *Klebsiella pneumoniae* strains producing a novel class A  $\beta$ -lactamase, GES-3, in a neonatal intensive care unit in Japan. *Antimicrob. Agents Chemother.* **48**:1960–1967.
13. Wachino, J.-I., Y. Doi, K. Yamane, N. Shibata, T. Yagi, T. Kubota, and Y. Arakawa. 2004. Molecular characterization of a cephamycin-hydrolyzing and inhibitor-resistant class A  $\beta$ -lactamase, GES-4, possessing a single G170S substitution in the  $\Omega$ -loop. *Antimicrob. Agents Chemother.* **48**:2905–2910.

**Seok Hoon Jeong**  
**Il Kwon Bae**  
**Doelman Kim**  
*Department of Laboratory Medicine*  
*College of Medicine*  
*Kosin University*  
*Busan 602-702*  
*Republic of Korea*

**Seong Geun Hong**  
*Department of Laboratory Medicine*  
*Pochon CHA University*  
*Pochon*  
*Republic of Korea*

**Jae Seok Song**  
**Jung Hun Lee**  
**Sang Hee Lee\***  
*Department of Biological Sciences*  
*Myongji University*  
*San 38-2 Namdong*  
*Yongin*  
*Kyunggi-do 449-728*  
*Republic of Korea*

\*Phone: 82 31 330 6195  
 Fax: 82 31 335 8249  
 E-mail: sangheelee@mju.ac.kr